

Euro Ewing 2012

Submission date 30/08/2013	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
Registration date 04/11/2013	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 16/04/2025	Condition category Cancer	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

<https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-looking-treatment-ewings-sarcoma-family-of-tumours-euro-ewing-2012>

Contact information

Type(s)

Scientific

Contact name

Prof Bernadette Brennan

Contact details

Royal Manchester Children's Hospital
Oxford Road
Manchester
United Kingdom
M13 9WL

Additional identifiers

Clinical Trials Information System (CTIS)

2012-002107-17

Protocol serial number

N/A

Study information

Scientific Title

International randomised controlled trial for the treatment of newly diagnosed Ewing's sarcoma family of tumours (ESFT)

Acronym

EE2012

Study objectives

For randomisation 1 - To compare the Vincristine, Ifosfamide, Doxorubicin, Etoposide (VIDE) strategy [VIDE induction and VAI/VAC (Vincristine, Actinomycin D, Ifosfamide/ Vincristine, Actinomycin D, Cyclophosphamide) consolidation] with the Vincristine, Doxorubicin, Cyclophosphamide/Ifosfamide, Etoposide (VDC/IE) strategy (compressed to VDC/IE induction and IE/VC consolidation).

Ethics approval required

Old ethics approval format

Ethics approval(s)

NRES Committee North West - Greater Manchester Central, 01/02/2013

Study design

Multi-centre international Phase III open-label randomized controlled trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Ewing's sarcoma

Interventions

Randomisation R1

At trial entry, patients will be randomised to one of the following treatment arms:

1. Arm A (VIDE strategy): VIDE induction; VAI/VAC consolidation

Induction chemotherapy: 6 cycles of VIDE

Consolidation chemotherapy: 1 cycle of VAI and 7 cycles of VAC or 8 cycles of VAI (unless randomised to Bu-Mel at R2)

2. Arm B (VDC/IE strategy): VDC/IE induction; IE/VC consolidation

Induction chemotherapy: 9 cycles of alternating VDC and IE

Consolidation chemotherapy: 5 cycles of alternating IE and VC (unless randomised to Bu-Mel at R2)

Randomisation R2zol

Following induction chemotherapy, patients who fulfil the eligibility criteria for R2zol and consent to take part in the randomisation will receive consolidation chemotherapy as allocated at trial entry and be randomised to receive either:

1. 9 cycles of zoledronic acid following the first cycle of consolidation chemotherapy (either VAI (Arm A) or IE (Arm B))

OR

2. No zoledronic acid

Randomisation R2loc

Following induction chemotherapy, patients who fulfil the eligibility criteria for R2loc and consent to take part in the randomisation will be randomised to receive either:

1. Consolidation chemotherapy as assigned at R1 either 8 cycles of VAI (Arm A) or 5 cycles of alternating IE and VC (Arm B)

OR

2. 1 cycle of VAI (Arm A) or 1 cycle of IE (Arm B), followed by high-dose treatment with busulfan and melphalan

Randomisation R2pulm

Following induction chemotherapy, patients who fulfil the eligibility criteria for R2pulm and consent to take part in the randomisation will be randomised to receive either:

1. Consolidation chemotherapy as assigned at R1 either 8 cycles of VAI (Arm A) or 5 cycles of alternating IE and VC (Arm B), plus lung irradiation

OR

2. 1 cycle of VAI (Arm A) or 1 cycle of IE (Arm B), followed by high-dose treatment with busulfan and melphalan

Drug names, frequency of administration and dose;

Arm A:

VIDE Vincristine (d1; 1.5mg/m²), Ifosfamide (d1, d2,d3; 3g/m²/d), Doxorubicin (d1,d2,d3; 20mg/m²/d), Etoposide (d1,d2,d3; 150mg/m²/d).

VAI Vincristine (d1; 1.5mg/m²), Actinomycin D (d1, d2; 0.75mg/m²/d), Ifosfamide (d1,d2; 3g/m²/d)

VAC Vincristine(d1; 1.5mg/m²), Actinomycin D (d1, d2; 0.75mg/m²/d), Cyclophosphamide (d1; 1500mg/m²)

Arm B:

VDC Vincristine(d1; 1.5mg/m²), Doxorubicin (d1, d2; 37.5mg/m²/d), Cyclophosphamide (d1; 1200mg/m²)

IE Ifosfamide (d1,d2,d3,d4,d5; 1800mg/m²/d), Etoposide (d1,d2,d3,d4,d5; 100mg/m²/d)

VC- Vincristine(d1; 2mg/m²), Cyclophosphamide (d1; 1200mg/m²)

Following treatment, patients will be followed up for progression and death until all trial objectives have been met.

Intervention Type

Drug

Phase

Phase III

Drug/device/biological/vaccine name(s)

Vincristine, ifosfamide, doxorubicin, etoposide, actinomycin D, cyclophosphamide

Primary outcome(s)

Event-free survival, defined as the time from randomisation to first event, where an event is progression without complete remission, recurrence (following complete remission), diagnosis of secondary malignancy or death. Patients who have not had an event will be censored at their last follow-up date. Patients lost to follow-up without an event will be censored at the date of their last consultation.

Key secondary outcome(s)

1. Overall survival defined as the time from randomisation to death, irrespective of cause. Surviving patients will be censored at their last follow-up date
2. Adverse events and toxicity - measured by CTCAE
3. Histological response of the primary tumour to induction chemotherapy if surgery is performed as local control - tumours will be graded using the Salzer-Kuntschik scale
4. Achievement of local control at the end of treatment, defined as complete surgical resection following induction chemotherapy, or no measurable disease assessed by end of treatment MRI scan, or no change in measurable residual tumour over a 6-month period from the end of treatment assessed by MRI scan at the end of treatment and 6 months after the end of treatment
5. Growth parameters and jaw osteonecrosis (R2zol only), defined as the change in Standard Deviation height score between baseline, end of treatment and throughout follow-up

Completion date

02/01/2025

Eligibility

Key inclusion criteria

R1 Inclusion criteria:

1. Histologically confirmed ESFT of bone or soft tissue
2. Localised or pulmonary and/or pleural metastatic disease
3. Age >2 years and <50 years (from second birthday to 49 years and 364 days) at the date of diagnostic biopsy
4. Randomisation ≤45 days after diagnostic biopsy/surgery
5. Patient assessed as medically fit to receive the treatment in either of the R1 treatment arms
6. No prior treatment for ESFT other than surgery
7. Documented negative pregnancy lactation test for female patients of childbearing potential
8. Patient agrees to use contraception during therapy and for 12 months after last trial treatment (females) or 5 months after last trial treatment (males), where applicable
9. Written informed consent from the patient and/or parent/legal guardian

R2zol Inclusion criteria:

1. No evidence of metastatic disease
2. Age >5 years (from fifth birthday) at date of randomization
3. Localised tumour of any tumour volume with surgery after chemotherapy alone, and good histological response to induction chemotherapy (<10% viability)
OR
4. Localised tumour with initial tumour volume <200ml with resection after chemotherapy and early radiotherapy, and good histological response to induction chemoradiotherapy (<10% viability)
OR
5. Localised tumour with initial tumour volume <200ml and surgery at diagnosis
OR
6. Localised tumour with initial tumour volume <200ml with resection after chemotherapy alone and extracorporeal irradiation of the primary tumour at surgery
OR
7. Localised unresected tumour with initial tumour volume <200ml and at least a partial radiological response to induction chemotherapy (≥50% regression of evaluable soft tissue component)

8. Consolidation chemotherapy as per protocol intended
9. Patient assessed medically fit to receive zoledronic acid if allocated
10. Written informed consent from the patient and/or parent/legal guardian

R2loc Inclusion criteria:

1. No evidence of metastatic disease
 2. Localised tumour of any tumour volume with surgery after chemotherapy alone, and poor histological response to induction chemotherapy ($\geq 10\%$ viability)
- OR
3. Localised tumour with initial tumour volume $\geq 200\text{ml}$ with surgery after chemotherapy and early radiotherapy, irrespective of histological response
- OR
4. Localised tumour with initial tumour volume $\geq 200\text{ml}$ and surgery at diagnosis
- OR
5. Localised tumour with initial tumour volume $\geq 200\text{ml}$ with extracorporeal irradiation of the primary tumour at surgery, and no progression under induction chemotherapy
- OR
6. Localised unresected tumour with initial tumour volume $< 200\text{ml}$ treated by radiation therapy alone as local therapy and with poor radiological response to induction chemotherapy ($< 50\%$ regression of evaluable soft tissue component) but no progression under induction chemotherapy
 7. Consolidation chemotherapy as per protocol intended
 8. Patient assessed medically fit to receive the treatment in either of the R2loc treatment arms
 9. Written informed consent from the patient and/or parent/legal guardian

R2pulm Inclusion criteria:

1. Pulmonary and/or pleural metastatic disease only at diagnosis
2. Partial response of the lung metastases and no progression of the primary tumour during induction chemotherapy
3. Consolidation chemotherapy as per protocol intended
4. Patient assessed medically fit to receive the treatment in either of the R2pulm treatment arms
5. Written informed consent from the patient and/or the parent/legal guardian

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Mixed

Sex

All

Total final enrolment

640

Key exclusion criteria

R1 Exclusion criteria:

1. Extrapulmonary metastatic disease

2. Contra-indication to the treatment in either of the R1 treatment arms
3. Second malignancy
4. Pregnant or breastfeeding women
5. Follow-up not possible due to social, geographic or psychological reasons

R2zol Exclusion criteria:

1. History of dental surgery (extraction or jaw surgery) in the 6 months preceding the start of zoledronic acid treatment, or planned dental surgery within the treatment period or within 6 months after the end of treatment
2. Ewings tumour of the maxilla or of the mandible
3. Progression of the primary tumour or appearance of new lesions

R2loc Exclusion criteria:

1. Radiotherapy required encompassing spine, a significant volume of digestive tract or lungs (such patients should be discussed during a web conference before randomisation for technique, volume, and dose validation with the national radiotherapy committee)
2. Progression of the primary tumour or appearance of new lesions

R2pulm Exclusion criteria:

1. Radiotherapy required encompassing spine, a significant volume of digestive tract or lungs (such patients should be discussed during a web conference before randomisation for technique, volume, and dose validation with the national radiotherapy committee)
2. Progression of the primary tumour or appearance of new lesions

Date of first enrolment

20/12/2013

Date of final enrolment

30/04/2019

Locations

Countries of recruitment

United Kingdom

England

France

Study participating centre

Royal Manchester Children's Hospital

Manchester

United Kingdom

M13 9WL

Sponsor information

Organisation

University of Birmingham (UK)

ROR

<https://ror.org/03angcq70>

Funder(s)

Funder type

Charity

Funder Name

Cancer Research UK (UK); C5952/A14745

Results and Publications

Individual participant data (IPD) sharing plan

The data sharing plans for the current study are unknown and will be made available at a later date

IPD sharing plan summary

Data sharing statement to be made available at a later date

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article		29/10/2022	16/12/2022	Yes	No
Protocol article	protocol	17/01/2020	20/01/2020	Yes	No
Other publications	Secondary analysis	20/12/2024	20/01/2025	Yes	No
Plain English results			17/03/2023	No	Yes